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Antibodies	  play	  an	   important	  role	   in	  therapy	  and	   investigative	  biomedical	  research.	  The	  TNF-­‐family	  
member	   Receptor	   Activator	   of	   NF-­‐κB	   (RANK)	   is	   known	   for	   its	   role	   in	   bone	   homeostasis	   and	   is	  
increasingly	   recognized	   as	   a	   central	   player	   in	   immune	   regulation	   and	   epithelial	   cell	   activation.	  
However,	  the	  study	  of	  RANK	  biology	  has	  been	  hampered	  by	  missing	  or	  insufficient	  characterization	  of	  
high	   affinity	   tools	   that	   recognize	   RANK.	  Here,	  we	   present	   a	   careful	   description	   and	   comparison	   of	  
two	   antibodies,	   RANK-­‐02	   obtained	   by	   phage	   display	   (Newa,	   2014	   [1])	   and	   R12-­‐31	   generated	   by	  
immunization	   (Kamijo	  2006	   [2]).	  We	  found	  that	  both	  antibodies	   recognized	  mouse	  RANK	  with	  high	  
affinity,	   while	   RANK-­‐02	   and	   R12-­‐31	   recognized	   human	   RANK	   with	   high	   and	   lower	   affinities,	  
respectively.	  Using	  a	  cell	  apoptosis	  assay	  based	  on	  stimulation	  of	  a	  RANK:Fas	   fusion	  protein,	  and	  a	  
cellular	   NF-­‐κB	   signaling	   assay,	   we	   showed	   that	   R12-­‐31	   was	   agonist	   for	   both	   species.	   R12-­‐31	  
interfered	   little	   or	   not	   at	   all	   with	   the	   binding	   of	   RANKL	   to	   RANK,	   in	   contrast	   to	   RANK-­‐02	   that	  
efficiently	   prevented	   this	   interaction.	   Depending	   on	   the	   assay	   and	   species,	   RANK-­‐02	   was	   either	   a	  
weak	  agonist	  or	  a	  partial	   antagonist	  of	  RANK.	  Both	  antibodies	   recognized	  human	  Langerhans	  cells,	  
previously	  shown	  to	  express	  RANK,	  while	  dermal	  dendritic	  cells	  were	  poorly	   labeled.	   In	  vivo	  R12-­‐31	  
agonist	  activity	  was	  demonstrated	  by	  its	  ability	  to	  induce	  the	  formation	  of	  intestinal	  villous	  microfold	  
cells	  in	  mice.	  This	  characterization	  of	  two	  monoclonal	  antibodies	  should	  now	  allow	  better	  evaluation	  
of	  their	  application	  as	  therapeutic	  reagents	  and	  investigative	  tools.	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1. Introduction	  	  
RANK	   (Receptor	   activator	  of	  NF-­‐κB)	   is	   a	   signaling	   receptor	   [3]	   engaged	  by	   its	   ligand	  RANKL	   [4]	  but	  
blocked	  by	  OPG	  (osteoprotegerin)	  that	  binds	  RANKL	  and	  prevents	   it	   from	  recognizing	  RANK	  [5]	  (for	  
review	   see	   [6]).	   The	   RANK-­‐RANKL-­‐OPG	   triad	   was	   originally	   identified	   as	   a	   regulator	   of	   bone	  mass	  
based	  on	  expression	  of	  the	  signaling	  receptor	  by	  pre-­‐osteoclasts	  and	  their	  differentiation	  into	  mature	  
osteoclasts	   by	   RANKL	   [5,7,8].	   Thus,	  mice	   deficient	   for	   or	   overexpressing	   any	   of	   the	   three	   proteins	  
display	   alterations	   in	   bone	   density.	   The	   triad	   is	   under	   the	   regulatory	   control	   by	   different	   factors,	  
among	  which	  sex	  hormones	  that	  link	  osteoporosis	  with	  menopausal	  hormonal	  changes	  or	  hormone	  
ablation	   therapy	   [9].	   Hence,	   a	   treatment	   of	   osteoporosis	   consists	   of	   the	   administration	   of	  
Denosumab,	   a	   human	  monoclonal	   RANKL-­‐neutralizing	   antibody	   [10].	   Similar	   reagents	   are	   used	   in	  
animal	   models,	   such	   as	   anti-­‐RANKL	   monoclonal	   antibody	   IK22-­‐5	   [2,11],	   RANK-­‐Fc	   fusion	   protein	  
[12,13]	  or	   recombinant	  OPG	   [14].	  A	  murine	  RANK-­‐specific	  monoclonal	   antibody	   (R12-­‐31)	  has	  been	  
generated,	  which	  was	  reported	  as	  unable	  to	  block	  the	  binding	  of	  RANK-­‐Fc	  to	  RANKL	  [2].	  Recently,	  an	  
antagonist	  RANK	  single-­‐chain	  variable	  fragment	  (scFv)	  reactive	  against	  human	  and	  mouse	  RANK	  has	  
been	  identified	  with	  a	  capacity	  to	  inhibit	  osteoclastogenesis	  [1].	  	  
The	  role	  of	  RANK	  is	  not	  limited	  to	  bone.	  Macrophages	  and	  dendritic	  cells	  are	  of	  the	  same	  lineage	  as	  
osteoclasts	  and	  express	  this	  receptor.	  RANK	  activation	  of	  these	  cells	  enhances	  the	  immune	  response	  
by	  increased	  cell	  survival	  and	  cytokine	  production	  [3,4,8,15-­‐20].	  Also	  epithelial	  cells	  are	  responsive	  to	  
RANKL.	  Thymic	  medullary	  epithelial	  cells	  require	  RANK	  activation	  signals	  for	  maturation	  [21-­‐23]	  (for	  
review	   see	   [24]),	   the	   development	   of	   intestinal	   microfold	   epithelial	   cells	   is	   dependent	   on	   RANK	  
signals	   [25,26],	   and	   RANK	   activation	   is	   required	   for	   the	   development	   of	   lactating	  mammary	   gland	  
epithelial	   cells	   during	   pregnancy	   [27-­‐29]	   (for	   review	   see	   [9]).	   However,	   although	   studies	   employ	  
RANK-­‐specific	  antibodies	  [13,25,30,31],	  these	  antibodies	  remain	  insufficiently	  characterized.	  	  
Therefore,	   in	   addition	   to	   potential	   therapeutic	   applications,	   specific	   antibodies	   are	   important	  
investigative	   tools	   to	   study	   the	   distribution	   and	   function	   of	   RANK,	   RANKL	   and	   OPG.	   The	   RANKL	  
monoclonal	   antibody	   IK22-­‐5	   [2]	  was	   used	   to	   demonstrate	   the	   production	   of	   RANKL	   by	   osteocytes	  
[32],	   T	   cells	   [32-­‐34],	   innate	   lymphoid	   cells	   [35]	   or	   lymph	   node	   stromal	   cells	   [36].	   The	  monoclonal	  
antibody	  R12-­‐31	  has	  shown	  RANK	  expression	  in	  synovial	  tissue	  and	  the	  myeloid	  cell	  lineage	  [37-­‐39].	  
Although	   reported	  as	  non-­‐antagonist	   [2]	   a	   rigorous	  analysis	  of	   its	   affinity	   and	   its	  biological	   activity	  
against	  mouse	  and	  human	  RANK	  had	  not	  been	  published.	  Recently,	  a	  scFv	  reactive	  against	  RANK	  has	  
been	   generated	   by	   phage	   display	   [1].	   It	   was	   shown	   to	   recognize	   human	   RANK	   by	   ELISA,	   by	  
immunoblot	  and	  by	  immunofluorescence	  on	  human	  osteoclasts	  and	  to	  inhibit	  osteoclastogenesis	  of	  
the	  murine	  RAW	  cell	  line.	  A	  detailed	  affinity	  and	  functional	  analysis	  of	  the	  scFv	  to	  evaluate	  its	  utility	  
in	  preclinical	  studies	  and	  investigative	  research	  was	  not	  performed.	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In	  the	  present	  study,	  we	  generated	  an	  antibody	  (RANK-­‐02)	  from	  the	  amino	  acid	  sequence	  of	  RANK-­‐
binding	   scFv	   and	   compared	   it	   with	   the	   anti-­‐RANK	   monoclonal	   antibody	   R12-­‐31	   with	   regard	   to	  
biological	   activity,	   interference	   with	   RANKL-­‐RANK	   interaction,	   distinct	   or	   shared	   epitopes	   and	  
recognition	  of	  primary	  RANK-­‐expressing	  cells.	  We	  find	  that	  both	  mAbs	  recognize	  human	  and	  mouse	  
RANK	  with	  high	  affinity	  but	  differ	  in	  their	  biological	  activity.	  Both	  mAbs	  were	  used	  to	  identify	  RANK-­‐
expressing	   primary	   cells	   and	   R12-­‐31	   was	   administered	   to	   mice	   to	   induce	   the	   differentiation	   of	  
intestinal	  microfold	  cells.	  	  
	  
2. Material	  and	  Methods	  	  
2.1. Production	  of	  RANK-­‐02	  antibody	  	  
The	  variable	  domains	  from	  the	  anti-­‐RANK	  scFv	  [1]	  were	  cloned	  into	  human	  IgG1	  heavy	  chain	  and	  light	  
chain	  expression	  vectors.	  These	  were	  co-­‐transfected	  into	  Chinese	  Hamster	  Ovary	  cells,	  and	  the	  IgG1,	  
named	  RANK-­‐01,	  was	  purified	  using	  MabSelect	  SuRe	  (GE	  Healthcare).	  RANK-­‐01	  demonstrated	  severe	  
aggregation	   on	   production,	   correlating	  with	   the	   aggregation	   pattern	   seen	   originally	   with	   the	   anti-­‐
RANK	   scFv	   (see	   Lam	   M.,	   Master’s	   thesis,	   University	   of	   Alberta,	   2011;	  
https://era.library.ualberta.ca/public/view/item/uuid:0036405c-­‐4d76-­‐49a0-­‐b2c7-­‐21c148af44f4).	  
Analysis	   of	   the	   variable	   domain	   sequence	   identified	   the	   absence	   of	   a	   canonical	   heavy	   chain	  
framework	   methionine	   residue	   at	   Kabat	   position	   82.	   Site	   directed	   mutagenesis	   was	   therefore	  
employed	  to	  insert	  the	  missing	  codon,	  generating	  a	  new	  human	  IgG	  heavy	  chain	  vector.	  This	  vector	  
was	   co-­‐transfected	   with	   the	   existing	   light	   chain	   vector	   to	   generate	   an	   improved	   anti-­‐RANK	   IgG1,	  
named	  RANK-­‐02,	  which	  did	  not	  aggregate	  on	  production.	  
2.2. ELISA	  	  
For	  ELISA	  with	  RANK-­‐02,	  recombinant	  human	  and	  mouse	  RANK-­‐Fc	  were	  coated	  overnight	  at	  20	  µg/ml	  
in	  PBS	  in	  96	  well	  plates	  (Nunc).	  Plates	  were	  washed	  with	  PBS,	  blocked	  for	  1	  h	  at	  room	  temperature	  
with	  PBS	  containing	  3%	  (w/v)	  milk	  powder	  and	  washed	  again.	  RANK-­‐02	  and	  an	  isotype	  control	  IgG1	  
were	  added,	  the	  plates	   incubated	  for	  one	  hour	  at	  room	  temperature	  and	  washed	  three	  times	  with	  
PBS/0.1%	  Tween	  20.	  Peroxidase-­‐coupled	  goat	  anti-­‐human	  kappa	  light	  chain	  antibody	  (Sigma,	  A7164)	  
was	  diluted	  1:5000,	  50	  µl	  was	  added	  to	  each	  well	  and	  the	  plates	  were	  incubated	  for	  1	  h.	  After	  three	  
washes	  with	  PBS/0.1%	  Tween	  20,	  50	  µl	  of	  tetramethylbenzidine	  (TMB,	  Sigma	  Aldrich)	  was	  added	  to	  
each	  well	  and	  incubated	  for	  five	  minutes	  before	  neutralization	  with	  50	  µl	  0.5	  M	  H2SO4.	  Plates	  were	  
read	  on	  a	  PerkinElmer	  Envision	  2100	  plate	  reader	  measuring	  absorbance	  at	  450	  nm	  and	  analyzed	  in	  
GraphPad	  PRISM.	  For	  ELISA	  with	  R12-­‐31,	  hRANK	  and	  mRANK-­‐Fc	  were	  coated	  at	  1	  µg/ml	  in	  PBS	  for	  3	  h	  
at	  37°C.	  Plates	  were	  blocked	  with	  PBS	  containing	  4	  %	  (w/v)	  milk	  powder	  and	  0.05	  %	  Tween	  20	  for	  1	  h	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37°C.	   Titrated	  amounts	  of	  R12-­‐31	  were	  added,	   the	  plates	   incubated	   for	  1	  h	  at	  37°C	  and	  washed	  3	  
times	  with	  PBS/0.05	  %	  Tween	  20.	  Peroxidase-­‐coupled	  goat	  anti-­‐rat	  IgG,	   light	  chain	  specific	  (Jackson	  
Immunoreasearch)	  was	  diluted	  1:5000,	  100	  µl	  was	  added	  to	  the	  plates	  and	  the	  plates	  were	  incubated	  
for	  1	  h	  at	  37°C.	  After	  three	  washes	  with	  PBS/0.05%	  Tween	  20,	  75µl	  of	   tetramethylbenzidine	  (TMB)	  
was	  added	   to	  each	  wells	  and	   then	  neutralized	  with	  25	  µl	  HCL	  1	  N.	  Plates	  were	   read	  at	  450	  nm	  on	  
Multiskan	  Ex	  (MTX	  Labsystems	  Inc.).	  
For	   the	   competitive	   ELISA	   assay,	   hRANK-­‐Fc	   was	   coated	   at	   5	   µg/ml.	   After	   blocking,	   wells	   were	  
incubated	   for	  1	  h	  at	  37°C	  with	   titrated	  amounts	  of	   the	   four	  antibodies	   (RANK-­‐02	  hIgG1	  anti-­‐RANK,	  
NIP288	  hIgG1	  control;	  R12.31	  rat	  IgG2a	  anti-­‐mRANK,	  rat	  IgG2a	  control).	  Without	  washing,	  a	  constant	  
volume	  of	  conditioned	  supernatant	  of	  293T	  cells	   transfected	  with	  Flag-­‐ACRP-­‐hRANKL	  (5	  µl)	  or	  Flag-­‐
mRANKL	  (20	  µl)	  was	  added	  to	  wells.	  Volumes	  were	  chosen	  for	  their	  abilities	  to	  generate	  a	  close	  to	  
maximal	   but	   non-­‐saturating	   signal.	   Binding	   of	   Flag-­‐ACRP-­‐hRANKL	   was	   revealed	   with	   biotin-­‐
conjugated	   M2-­‐antibody	   (0.5µg/ml)	   (Sigma)	   and	   streptavidin-­‐HRP	   (Jackson	   immunoresearch)	  
(1/4000).	  
2.3. Affinity	  measurements	  by	  surface	  plasmon	  resonance	  
Real-­‐time	  binding	  kinetics	  to	  mRANK-­‐Fc	  (Sigma-­‐Aldrich)	  and	  hRANK-­‐Fc	  (purified	  from	  transfected	  HEK	  
293	   cells)	  were	  measured	   on	   a	   BIAcore	   3000.	   The	   proteins	  were	   immobilized	   by	   injecting	   6	   µg	   of	  
RANK-­‐Fc	   on	   a	   CM5	   chip	   activated	   with	   N-­‐ethyl-­‐N’-­‐dimethylaminopropyl	   carbodiimide/N-­‐
hydroxysuccinimide	  (GE-­‐Healthcare,	  Uppsala,	  Sweden)	  in	  formate	  buffer,	  pH	  4.3,	  which	  gave	  a	  signal	  
of	  approximately	  2000	  RU.	  Free	  active	  sites	  were	  quenched	  with	  ethanolamine	  hydrochloride,	  pH8.5.	  
Binding	  was	  performed	  in	  10	  mM	  HEPES-­‐buffered	  saline	  containing	  0.005	  %	  v/v	  surfactant	  P20	  at	  25	  
°C	  with	  a	  constant	  flow	  rate	  of	  30	  µl/min.	  The	  antibodies	  were	  injected	  at	  0.1	  nM	  to	  4	  nM	  (RANK-­‐02)	  
and	  2	  nM	  to	  70	  nM	  for	  R12-­‐31.	  The	  sensor	  chip	  was	  regenerated	  after	  each	  experiment	  by	  injecting	  
10	  µl	  of	  EDTA	  0.5	  M,	  pH	  8.	  The	  kinetic	  parameters	  were	  calculated	  using	  the	  BIAeval	  4.1	  software,	  
and	   the	   analysis	   used	   the	   simple	   Langmuir	   binding	   model	   kon/koff.	   Specific	   binding	   profiles	   were	  
obtained	  by	   subtracting	   the	   response	   signal	   from	   the	   control	   channel	   (activated/desactivated)	   and	  
from	  blank-­‐buffer	  injection.	  The	  fitting	  of	  each	  model	  was	  judged	  by	  the	  χ²	  value	  and	  randomness	  of	  
residue	  distribution	  compared	  to	  the	  theoretical	  model	  (Langmuir	  binding	  1:1).	  	  
2.4. Flow	  cytometry	  
All	  labelling	  were	  performed	  at	  4°C	  in	  PBS,	  2%	  fetal	  calf	  serum	  (FCS),	  2.5	  mM	  EDTA	  with	  the	  following	  
antibodies:	  anti-­‐RANK	  R12-­‐31,	  anti-­‐RANK	  RANK-­‐02,	  rat	  IgG2a	  isotype	  control	  (BectonDickinson	  [BD]-­‐
Pharmingen,	  San	  Jose,	  CA,	  USA),	  NIP228	  human	  IgG1	  isotype	  control	  (MedImmune	  Inc.),	  donkey	  anti-­‐
rat	   Ig-­‐PE	   (Jackson	   Immunoresearch),	  donkey	  anti-­‐human	   Ig-­‐PE	   (Jackson	   Immunoresearch).	   For	   flow	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cytometric	   analysis	   of	   human	   skin	   the	   following	   antibodies	   were	   used:	   anti-­‐HLA	   DR	   (L203,	   R&D	  
Systems),	  anti-­‐DC-­‐SIGN	  (DCN46,	  BD-­‐Pharmingen),	  anti-­‐Langerin	  (929F3.01,	  Dendritics,	  Lyon,	  France),	  
anti-­‐CD14	   (M5E2,	   BD-­‐Pharmingen).	   Fixable	   Viability	   Dye	   eFluor®	   780	   (ebioscience)	   was	   used	   to	  
exclude	  the	  dead	  cells.	  Flow	  cytometry	  was	  performed	  on	  a	  FACS-­‐Calibur	  (BD)	  or	  Gallios	  (Beckman-­‐
Coulter,	  Fullerton,	  CA,	  USA)	  and	   the	   flow	  cytometry	  data	  were	  analyzed	  using	   the	  FlowJo	  software	  
(Treestar,	  Ashland,	  OR,	  USA).	  Langerhans	  and	  dermal	  dendritic	  cells	  were	  isolated	  from	  human	  skin	  
as	  described	  [40].	  	  
To	  determine	  recognition	  of	  different	  epitopes,	  Jurkat	  JOM2	  mRANK:Fas	  and	  Jurkat	  JOM2	  hRANK:Fas	  
were	   incubated	   on	   ice	   for	   15	   min	   with	   increasing	   amounts	   of	   unlabeled	   competitor	   antibody,	  
followed	  without	  washing	  by	  a	  fixed	  concentration	  of	  biotinylated	  test	  mAb	  for	  20	  min	  on	  ice.	  Cells	  
were	  then	  washed	  and	  binding	  of	  test	  mAb	  revealed	  with	  PE-­‐conjugated	  streptavidin.	  	  
2.5. Cell	  culture	  
All	  cells	  were	  maintained	  in	  a	  humidified	  incubator	  with	  5%	  CO2	  at	  37°C.	  Jurkat	  JOM2,	  Jurkat	  JOM2	  
mRANK:Fas	  and	  Jurkat	  JOM2	  hRANK:Fas,	  were	  grown	  in	  RPMI	  1640	  medium	  supplemented	  with	  10	  %	  
FCS.	  Jurkat	  JOM2	  mRANK:Fas	  and	  Jurkat	  JOM2	  hRANK:Fas	  were	  generated	  according	  to	  a	  described	  
protocol	  [41,42].	  HEK	  293	  cells	  stably	  transfected	  with	  mRANK	  [31]	  or	  with	  hRANK	  (a	  kind	  gift	  of	  Dr.	  
D.Heymann,	   University	   of	   Nantes,	   France)	   were	   grown	   in	   DMEM	   supplemented	   with	   10	   %	   FCS,	  
gentamicin	  (10	  µg/ml)	  and	  penicillin/streptomycin	  (100	  U/ml).	  G418	  selection	  (500	  µg/ml)	  was	  used	  
to	  maintain	  HEK	  293-­‐mRANK	  cell	  line.	  	  
2.5.1. Cell	  viability	  assay	  
Jurkat	   JOM2,	   Jurkat	   JOM2	   mRANK:Fas	   and	   Jurkat	   JOM2	   hRANK:Fas	   (50x103	   cells/100	   µl)	   were	  
incubated	   for	   16	   h	   with	   ligands	   or	   antibodies	   as	   indicated.	   For	   RANK-­‐02	   blocking	   assay,	   75x103	  
cells/100	   µl	  were	   incubated	   for	   1	   h	  with	   50	   µg/ml	   RANK-­‐02	   antibody	   before	   treatment	  with	  GST-­‐
mRANKL	   for	   6h.	   Cell	   viability	   was	   then	   assessed	   using	   the	   Cell	   titer	   96	   Aqueous	   One	   Solution	  
(Promega)	   according	   to	  manufacturer’s	   instructions.	  Absorbance	  was	  measured	   at	   490	  nm	  using	   a	  
Mithras	  LB940	  reader	  (Berthold	  technologies).	  All	  assays	  were	  performed	  in	  duplicates	  and	  repeated	  
at	  least	  three	  times.	  Untreated	  cells	  were	  set	  at	  100	  %	  control	  level	  of	  cell	  viability.	  
2.5.2. NF-­‐κB	  reporter	  gene	  assay	  	  
HEK	  293-­‐mRANK	  and	  HEK	  293-­‐hRANK	  were	   transiently	   transfected	  with	  NF-­‐κB1	   luciferase	   reporter	  
vector	   (Panomics)	   and	   an	   internal	   control	   EF1-­‐β-­‐galactosidase	   plasmid	   (a	   kind	   gift	   from	   Sylvie	  
Mémet,	   Institut	   Pasteur,	   Paris,	   France)	   using	   lipofectamine	   2000	   (Life	   Technologies).	   24	   h	   after	  
transfection,	   cells	  were	   treated	   in	  duplicates	  with	   ligands	  or	   antibodies	   as	   indicated.	  After	   16	  h	  of	  
treatment,	  cells	  were	  lysed	  using	  reporter	  lysis	  buffer	  (Promega).	  Luciferase	  activity	  was	  measured	  by	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luminescence	   on	   a	   Mithras	   LB940	   reader	   (Berthold	   Technologies)	   using	   luciferase	   assay	   system	  
(Promega).	   Beta-­‐galactosidase	   activity	   was	   used	   to	   normalize	   the	   luminescence	   values	   for	  
transfection	   efficiency.	   It	   was	  measured	   by	   reading	   absorbance	   at	   450	   nm	   on	  Multiskan	   Ex	   (MTX	  
Labsystems	  Inc.)	  using	  β-­‐galactosidase	  enzyme	  assay	  system	  (Promega).	  To	  assay	  RANK-­‐02	  antagonist	  
activity,	   transfected	   HEK	   293-­‐mRANK	   were	   pretreated	   for	   1	   h	   with	   RANK-­‐02	   at	   50	   µg/ml	   before	  
adding	   GST-­‐mRANKL	   at	   0.1	   µg/ml	   for	   6	   h.	   IK22-­‐5	   anti-­‐RANKL	   antibody	  was	   used	   at	   10	   µg/ml	   as	   a	  
positive	  control	  for	  inhibition	  of	  RANK-­‐RANKL	  interaction.	  	  
2.6. Villous	  microfold	  cell	  induction	  by	  R12-­‐31	  and	  GST-­‐mRANKL	  administration	  	  
C57BL/6	  mice	  were	  treated	  i.p.	  with	  100	  µg	  of	  anti-­‐RANK	  R12-­‐31	  antibody	  on	  days	  0,	  2,	  and	  4	  or	  with	  
50	  µg	  i.p.	  of	  GST-­‐mRANKL	  on	  day	  0	  plus	  100	  µg	  GST-­‐mRANKL	  s.c.	  	  on	  days	  0-­‐4.	  On	  day	  5,	  the	  proximal	  
ileum	  was	   removed	   for	   tissue	  analysis.	   The	   tissue	  was	   stained	  with	   rhodamine-­‐UEA-­‐I	   as	  previously	  
described	  [25].	  	  
2.7. Serum	  TRACP	  5b	  detection	  after	  RANK-­‐02	  and	  GST-­‐mRANKL	  administration	  
Adult	   C57BL/6	   mice	   were	   treated	   i.p	   with	   RANK-­‐02	   antibody	   1	   h	   before	   administration	   of	   GST-­‐
mRANKL	  (25	  µg/mouse)	  i.p.	  Fifteen	  hours	  afterwards,	  serum	  was	  taken	  for	  the	  measure	  of	  TRACP	  5b	  
by	  ELISA	  according	  to	  the	  manufacturer’s	  instructions	  (Immunodiagnostic	  systems).	  
2.8. Statistical	  analysis	  	  
Statistical	   significance	   was	   calculated	   by	   one	   or	   two	   way	   ANOVA/Bonferroni	   using	   the	   PRISM	  
software.	  *<0.05,	  **<0.01,	  ***<0.001,	  ****<0.0001,	  ns=	  not	  statistically	  significant.	  
	  
3. Results	  	  
3.1. Specificity	  and	  affinity	  of	  R12-­‐31	  and	  RANK-­‐02	  for	  mouse	  RANK	  
The	   nucleic	   acid	   sequence	   obtained	   from	   a	   human	   RANK-­‐Fc-­‐selected	   scFv	   [1]	   was	   modified	   to	  
generate	   a	   recombinant	   human	   antibody,	   termed	   RANK-­‐02	   (see	  Material	   and	  Methods).	  We	   first	  
investigated	  its	  affinity	  and	  specificity	  for	  mouse	  (m)	  RANK	  and	  could	  expect	  recognition	  of	  mRANK	  
because	  the	  scFv	   inhibited	  osteoclast	  formation	  of	  a	  murine	  cell	   line.	  However,	  no	  further	  analyses	  
were	  reported	  [1].	  To	  first	  evaluate	  binding	  to	  mRANK	  we	  performed	  an	  ELISA	  in	  comparison	  with	  the	  
known	   RANK-­‐specific	   mAb	   R12-­‐31	   [2].	   Both	   antibodies	   recognized	   the	   fusion	   protein	   in	   a	   dose	  
dependent	   manner	   (Fig.	   1A).	   Affinities	   of	   both	   mAbs	   were	   determined	   by	   surface	   plasmon	  
resonance,	  and	  they	  bound	  mRANK-­‐Fc	  with	  high	  affinity	  (~0.2	  nM)	  (Table	  1).	  To	  further	  confirm	  their	  
specificity,	   we	   performed	   flow	   cytometry	   analysis	   on	   two	   different	   cell	   lines	   both	   expressing	   the	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extracellular	   domain	   of	   mRANK	   and	   compared	   the	   signal	   intensity	   with	   that	   obtained	   with	   the	  
parental	  cell	   lines.	  We	  used	  the	  Jurkat	  human	  T	  cell	   line,	  deficient	  for	  Fas	  (Jurkat	  JOM2)	  and	  stably	  
expressing	  the	  mRANK	  extracellular	  domain	  fused	  to	  the	  transmembrane	  and	   intracellular	  domains	  
of	  human	  Fas	  (Jurkat	  JOM2	  mRANK:Fas)	  [41],	  and	  the	  human	  embryonic	  kidney	  cells	  HEK	  293	  cells,	  
stably	   transfected	   with	   full-­‐length	   mRANK	   (HEK	   293-­‐mRANK).	   The	   antibodies	   failed	   to	   recognize	  
parental	   cell	   lines	   but	   bound	   the	   mRANK-­‐expressing	   cells	   (Fig.	   1B).	   The	   analysis	   of	   the	   mean	  
fluorescence	   intensity	   showed	   that	   R12-­‐31	   generated	   a	   slightly	   stronger	   signal	   than	   RANK-­‐02	  
(Supplementary	  Fig.	  1A,	  B).	  Therefore,	  RANK-­‐02	  and	  R12-­‐31	  specifically	   recognize	   the	  extracellular	  
domain	  of	  mRANK	  with	  high	  affinity.	  	  
3.2. Biological	  activity	  of	  R12-­‐31	  and	  RANK-­‐02	  on	  mouse	  RANK	  
Like	   any	   TNF	   receptor	   superfamily	   member,	   RANK	   signaling	   requires	   multimerization	   to	   recruit	  
downstream	  signaling	  adaptors.	  The	  biological	  activity	  of	  antibodies	  was	  first	  characterized	  using	  the	  
JOM2	  mRANK:Fas	  cell	   line.	  A	  comparison	  between	  JOM2	  mRANK:Fas	  cells	  and	  the	  parental	  cell	   line	  
showed	   that	   GST-­‐mRANKL	   specifically	   killed	   JOM2	  mRANK:Fas	   cells	   by	   engaging	   the	   surrogate	   Fas	  
apoptotic	  signaling	  pathway	  (Supplementary	  Fig.2A).	  Apoptosis	  was	  not	  observed	  in	  response	  to	  GST	  
alone	   (Supplementary	   Fig.2B).	   Incubation	   of	   JOM2	  mRANK:Fas	   cells	  with	   R12-­‐31	   led	   to	   cell	   death	  
(Fig.	   2A),	   while	   its	   isotype	   control	   (data	   not	   shown)	   and	   the	   RANK-­‐02	   antibody	   had	   no	   observed	  
effect	   even	   at	   high	   concentrations	   (Fig.	   2B).	   These	   results	   suggest	   that	   R12-­‐31	   and	   RANK-­‐02	  
antibodies	  have	  distinct	  biological	  properties.	  These	  findings	  were	  validated	  using	  a	  canonical	  NF-­‐κB	  
activation	  assay	   in	  HEK293	  cells	  transfected	  with	  full-­‐length	  mRANK.	  Stimulation	  of	  these	  cells	  with	  
GST-­‐mRANKL	  as	  a	  positive	  control	  or	  with	  R12-­‐31	  both	  induced	  NF-­‐κB	  activation,	  while	  RANK-­‐02	  did	  
not	  (Fig.	  2C,	  D).	  R12-­‐31	  and	  RANK-­‐02	  were	  used	  at	  25	  µg/ml	  and	  50	  µg/ml,	  respectively,	  to	  be	  in	  line	  
with	   the	   concentrations	   of	   100	   nM	   of	   scFV	   used	   in	   Newa	   et	   al.	   and	   the	   expected	   low	   biological	  
activity	   of	   the	   latter	   (Fig.	   2B)	   [1].	   Because	   the	   RANK-­‐02	   equivalent	   scFv	   could	   inhibit	  
osteoclastogenesis	   [1],	   we	   next	   assayed	   the	   antagonist	   activity	   of	   RANK-­‐02.	   Indeed,	   when	   Jurkat	  
JOM2	  mRANK:Fas	  cells	  were	  pre-­‐incubated	  with	  50	  µg/ml	  RANK-­‐02	  prior	  to	  addition	  of	  recombinant	  
mRANKL,	  cell	  death	  was	  almost	  completely	   inhibited	  (Fig.	  2E).	  Similarly,	   the	  anti-­‐RANK-­‐02	  antibody	  
diminished	  NF-­‐κB	  activation	  by	  recombinant	  RANKL	  (Fig.	  2F),	  but	  again	  less	  efficiently	  than	  the	  anti-­‐
RANKL	  antibody	  IK22-­‐5	  (Fig.	  2E,	  F).	  Altogether,	  the	  above	  data	  demonstrate	  that	  R12-­‐31	  and	  RANK-­‐
02	  bind	  mRANK	  with	  similar	  affinities,	  but	  differ	  in	  their	  biological	  effects.	  
3.3. Specificity	  and	  affinity	  of	  R12-­‐31	  and	  RANK-­‐02	  for	  human	  RANK	  
We	   extended	   these	   analyses	   to	   human	   (h)	   RANK	   and	   observed	   that	   RANK-­‐02	   and	   R12-­‐31	   also	  
recognized	  hRANK-­‐Fc	  in	  ELISA	  (Fig.	  3A).	  We	  next	  compared	  the	  affinity	  of	  both	  antibodies	  to	  hRANK-­‐
9	  
	  
Fc	   by	   surface	   plasmon	   resonance	   and	   obtained	   an	   affinity	   of	   RANK-­‐02	   for	   hRANK	   in	   the	  
subnanomolar	   range	   (0.12	   nM)	  while	   R12-­‐31	   recognized	   hRANK	  with	   a	   200-­‐fold	   lower	   affinity	   (25	  
nM)	   (Table	   1).	   To	   test	   if	   the	   antibodies	   recognized	   hRANK-­‐transfected	   cell	   lines,	   we	   used	   JOM2	  
hRANK:Fas	  cells	  and	  HEK	  293	  cells	  transfected	  with	  full	  length	  hRANK.	  Both	  antibodies	  bound	  Jurkat	  
JOM2	   hRANK:Fas	   and	   HEK	   293-­‐hRANK,	   but	   not	   their	   parent	   cell	   lines	   (Fig.	   3B).	   Although	   R12-­‐31	  
labelled	  hRANK-­‐expressing	  cells	  by	  flow	  cytometry,	  it	  did	  so	  less	  efficiently	  than	  RANK-­‐02,	  as	  its	  MFI	  
values	  were	  lower	  compared	  to	  those	  obtained	  with	  RANK-­‐02	  (Supplementary	  Fig.	  1C,	  D).	  This	  may	  
be	  attributable	  to	  the	   lower	  affinity	  of	  R12-­‐31	  to	  hRANK.	  This	  confirms	  that	  the	  specificity	  of	  these	  
antibodies	  extends	  to	  hRANK.	  	  
3.4. Biological	  effects	  of	  R12-­‐31	  and	  RANK-­‐02	  on	  human	  RANK	  
We	  used	  cell	  lines	  expressing	  hRANK	  or	  hRANK:Fas	  fusion	  protein	  to	  investigate	  the	  biological	  effects	  
of	   the	   antibodies	   on	   hRANK.	   R12-­‐31	   again	   displayed	   agonist	   activity	   (Fig.	   4A)	  with	   an	   EC50	   of	   5.7	  
ng/ml,	   comparable	   to	   that	   observed	   with	   mRANK:Fas	   cells	   (EC50	   of	   2.4	   ng/ml).	   However,	   as	  
hRANK:Fas	   reporter	   cells	   are	   about	   6	   times	   more	   sensitive	   than	   mRANK:Fas	   reporter	   cells	  
(Supplementary	   Fig.	   2C,	  D),	   the	   agonist	   activity	  of	  R12-­‐31	   is	   altogether	   roughly	  more	   than	  10-­‐fold	  
less	   efficient	   on	   hRANK:Fas	   cells	   compared	   to	   mRANK:Fas	   cells,	   in	   line	   with	   its	   lower	   affinity	   for	  
hRANK.	  RANK-­‐02	  exhibited	  weak	  agonist	  activity	  on	  hRANK:Fas	  cells	  at	  high	  concentrations	  (EC50	  of	  
470	  ng/ml)	  that	  however	  never	  induced	  complete	  apoptosis	  (Fig.	  4B).	  This	  apparent	  discrepancy	  with	  
results	   obtained	   on	   mRANK:Fas	   cells	   might	   be	   explained	   by	   the	   intrinsic	   higher	   sensitivity	   of	  
hRANK:Fas	   cells	   to	  apoptosis.	   Isotype	   controls	  had	  no	  effect	  at	   the	  highest	  dose	   tested	   for	  R12-­‐31	  
and	   RANK-­‐02	   (Fig.	   4C).	  We	   next	   performed	   the	  NF-­‐κB	   reporter	   assay	   in	   HEK	   293-­‐hRANK	   cells	   and	  
observed	   agonist	   effects	   for	   both	   mAbs	   with	   RANK-­‐02	   displaying	   again	   weaker	   activity	   (Fig.	   4D).	  
These	  findings	  confirm	  that	  R12-­‐31	  is	  an	  agonist	  for	  RANK,	  across	  the	  species,	  and	  revealed	  a	  weak	  
agonist	  effect	  of	  RANK-­‐02	  on	  hRANK.	  	  
3.5. RANK-­‐02	   efficiently	   interfered	   with	   RANK-­‐RANKL	   interaction	   and	   recognized	   an	  
epitope	  distinct	  from	  R12-­‐31	  
In	  order	  to	  understand	  the	  molecular	  mechanism	  by	  which	  RANK-­‐02	  antagonized	  the	  action	  of	  RANKL	  
on	  RANK-­‐expressing	  cells,	  we	  measured	  its	  ability	  to	  interfere	  with	  the	  binding	  of	  Flag-­‐RANKL	  to	  Fc-­‐
RANK	   in	   an	   ELISA-­‐based	   assay.	   Pre-­‐incubation	   of	   coated	   hRANK-­‐Fc	   with	   RANK-­‐02	   efficiently	  
prevented	   further	  binding	  of	  human	  or	  mouse	  RANKL,	   strongly	  suggesting	   that	   the	  binding	  sites	  of	  
RANK-­‐02	  and	  RANKL	  on	  hRANK	  overlap	  (Fig.	  5A).	  In	  contrast,	  pre-­‐incubation	  of	  coated	  hRANK-­‐Fc	  with	  
the	  mAb	   R12-­‐31	   did	   not	   prevent	   the	   binding	   of	   hRANKL,	   and	   only	  marginally	   interfered	   with	   the	  
binding	  of	  mRANKL,	  indicating	  that	  its	  binding	  site	  is	  distinct,	  or	  only	  very	  partially	  common	  with	  that	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of	  hRANKL	  and	  mRANKL,	  respectively	  (Fig.	  5A).	  Control	  antibodies	  did	  not	  interfere	  with	  RANKL-­‐RANK	  
interactions.	  To	  further	  address	  the	  question	  of	  overlapping	  or	  distinct	  epitopes	  between	  the	  mAbs,	  
we	   performed	   a	   competition	   assay	   for	   their	   binding	   to	   hRANK-­‐,	   or	   to	   mRANK-­‐expressing	   cells	   by	  
FACS.	   To	   this	   end,	   h/mRANK:Fas	   cells	  were	   incubated	  with	   increasing	   concentrations	   of	   unlabeled	  
RANK-­‐02,	   R12-­‐31,	   or	   their	   isotype	   controls,	   followed	   by	   biotinylated	   RANK-­‐02	   and	   phycoerythrin-­‐
conjugated	  streptavidin.	  Cell	  labelling	  was	  determined	  by	  FACS	  and	  the	  MFI	  calculated.	  This	  was	  also	  
performed	   for	   R12-­‐31.	   As	   depicted	   in	   supplementary	   Fig.	   3	   and	   summarized	   in	   Fig.	   5B,	   RANK-­‐02	  
competes	  only	  with	  biotinylated	  RANK-­‐02	  on	  h/mRANK,	  and	  R12-­‐31	  competes	  only	  with	  biotinylated	  
R12-­‐31	  on	  h/mRANK,	  showing	  that	  RANK-­‐02	  and	  R12-­‐31	  recognize	  distinct	  epitopes.	  	  
3.6. Labelling	  of	  RANK	  on	  primary	  human	  Langerhans	  cells	  with	  RANK-­‐02	  and	  R12-­‐31	  
To	   investigate	   whether	   the	   antibodies	   are	   suitable	   for	   the	   detection	   of	   endogenous	   RANK,	   we	  
incubated	   them	  with	   primary	   human	   skin	   dermal	   dendritic	   cells	   and	   Langerhans	   cells.	   Langerhans	  
cells	   have	   previously	   been	   shown	   to	   express	   RANK	   using	   the	   mAb683	   (R&D	   Systems)	   [18,19].	  
Whether	   the	   related	  dermal	  dendritic	   cells	  also	  express	  RANK	   is	  not	  known.	  After	  allowing	  cells	   to	  
migrate	   from	   human	   skin	   into	   culture	   medium,	   they	   were	   harvested	   and	   labelled	   for	   different	  
markers	  to	  identify	  three	  subsets	  (Fig.	  6A).	  The	  Langerhans	  cells	  (subset	  I)	  was	  clearly	  recognized	  by	  
both	  RANK-­‐02	  and	  R12-­‐31	  mAbs	  (Fig.	  6B),	  the	  CD14-­‐	  dermal	  dendritic	  cells	  (subset	  II)	  expressed	  low	  
levels	  of	  RANK,	  and	  the	  CD14+	  population	  (subset	  III)	  was	  devoid	  of	  RANK	  (Fig.	  6C,	  D).	  Both	  mAbs	  are	  
valid	  tools	  to	  detect	  RANK	  expression	  on	  primary	  cells,	  as	  the	  values	  of	  %	  positive	  Langerhans	  cells	  
(Fig.	  6E)	  and	  the	  MFI	  (Fig.	  6F)	  were	  not	  significantly	  different.	  The	  data	  show	  that	  migrated	  human	  
Langerhans	  cells	  express	  the	  highest	  levels	  of	  RANK	  among	  human	  skin	  dendritic	  cells.	  	  
3.7. Assessment	  of	  antibody	  activity	  in	  vivo	  	  
To	   assess	   mAb	   activities	   in	   vivo,	   we	   determined	   the	   capacity	   of	   RANK-­‐02	   to	   inhibit	   recombinant	  
RANKL	   to	   activate	   the	   release	   of	   the	   tartrate-­‐resistant	   acid	   phosphatase	   isoform	   b	   (TRACP	   5b)	   by	  
osteoclasts	   [43,44].	  Mice	   received	   increasing	  doses	  of	  RANK-­‐02	  1	  h	  before	  administration	  of	  25	  µg	  
GST-­‐RANKL	  (1mg/kg),	  and	  TRACP	  5b	  was	  measured	  in	  the	  serum	  by	  ELISA	  15	  h	  later.	  RANKL	  resulted	  
in	  a	  30%	   increase	  of	  TRACP	  5b,	  however	  RANK-­‐02	  did	  not	  significantly	  alter	   this	   level	   (Fig.	  7A).	  We	  
had	  previously	  shown	  that	  the	  administration	  of	  GST-­‐mRANKL	  induced	  the	  ectopic	  differentiation	  of	  
cells	   of	   the	   villous	   small	   intestinal	   epithelium	   into	   microfold	   (M)	   cells	   [25].	   We	   therefore	   tested	  
whether	  R12-­‐31	  could	  induce	  the	  formation	  of	  villous	  M	  cells.	  To	  this	  end,	  mice	  were	  left	  untreated	  
or	   received	   either	   R12-­‐31	   or	   GST-­‐mRANKL	   for	   5	   days.	   Thin	   strips	   of	   intestinal	   tissue	   were	   then	  
prepared	  for	  staining	  with	  rhodamine	  UEA-­‐I	  that	  labels	  M	  cells.	  Small	  intestinal	  UEA-­‐I+	  villous	  M	  cells	  
were	   readily	   observed	   in	   mice	   treated	   with	   R12-­‐31	   or	   with	   recombinant	   RANKL,	   in	   contrast	   to	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untreated	  mice	  that	  showed	  only	  few	  UEA-­‐I+	  cells	  (Fig.	  7B,	  C).	  This	  shows	  that	  R12-­‐31	  exerts	  agonist	  
activity	  in	  vivo.	  	  
	  
4. Discussion	  
We	  estimated	  that	  a	  detailed	  characterization	  of	  two	  RANK-­‐specific	  mAbs,	  one	  derived	  from	  a	  scFv	  
selected	  against	  hRANK	  and	  one	  generated	   in	   the	   rat	   against	  mRANK	   [1,2],	  would	  be	  beneficial	   to	  
their	  evaluation	  as	  therapeutic	  reagents	  and	  investigative	  tools.	  We	  found	  that	  both	  mAbs	  bound	  to	  
mouse	   and	   human	   RANK-­‐Fc	   in	   ELISA	   and	   surface	   plasmon	   resonance	   and	   recognized	   RANK-­‐
expressing	   cell	   lines	   or	   primary	   cells	   in	   flow	   cytometry.	   The	  mAbs	   recognized	   distinct	   epitopes	   on	  
RANK	  and	  displayed	  differences	   in	   their	   biological	   activities	   and	   in	   their	   capacity	   to	   inhibit	   RANKL-­‐
RANK	  interaction.	  We	  showed	  that	  the	  agonist	  mAb	  R12-­‐31	  is	  functional	  in	  vivo.	  	  
RANK-­‐02	  and	  R12-­‐31	  recognized	  human	  and	  mouse	  RANK	   in	  ELISA,	  plasmon	  resonance	  and	   in	   flow	  
cytometry.	  Cross-­‐reactivity	  between	  RANK	   from	  both	   species	  can	  be	  expected	  because	  mouse	  and	  
human	  RANK	  share	  73%	  sequence	  identity	  [3].	  R12-­‐31,	  which	  was	  generated	  by	  immunization	  of	  rats	  
with	  mRANK-­‐transfected	  cells,	  had	  a	  high	  affinity	  for	  mRANK	  but	  a	  lower	  affinity	  for	  hRANK.	  Although	  
R12-­‐31	  comparatively	   stained	  mRANK-­‐transfected	  cells	  better	   than	  hRANK-­‐transfected	  ones,	   it	  was	  
good	  enough	  to	  label	  human	  Langerhans	  cells.	  RANK-­‐02	  was	  obtained	  using	  a	  phage	  display	  selection	  
with	  the	  hRANK	  extracellular	  domain	  and	  had	  a	  high	  affinity	  for	  both	  human	  and	  mouse	  RANK.	  Thus,	  
this	  mAb	  may	  be	  the	  reagent	  of	  choice	  to	  detect	  human	  cells	  expressing	  low	  levels	  of	  RANK,	  such	  as	  
CD14-­‐	  dermal	  dendritic	  cells.	  	  
Biological	   activities	   of	   these	   antibodies	   were	   determined	   using	   cell	   lines	   stably	   expressing	   either	  
RANK:Fas	  fusion	  proteins	  or	  full-­‐length	  RANKs.	  Data	  showed	  that	  R12-­‐31	  was	  agonist	  on	  both	  human	  
and	  mouse	  RANK,	   however,	   in	   line	  with	   its	   higher	   affinity,	   the	   activity	  was	   stronger	   on	  mRANK.	  A	  
competitive	   ELISA	   further	   revealed	   that	   R12-­‐31	  most	   probably	   recognized	   a	   site	   distinct	   from	   that	  
occupied	  by	  RANKL.	  This	   is	  compatible	  with	  a	  scenario	  upon	  which	  engagement	  of	  RANK	  by	  R12-­‐31	  
induces	  conformational	   changes	  and/or	  aggregation	  of	  RANK	   that	  all	   in	  all	  mimic	   the	  action	  of	   the	  
ligand.	   The	   biological	   activity	   of	   R12-­‐31	   was	   demonstrated	   in	   vivo	   by	   its	   ability	   to	   trigger	   the	  
conversion	  of	   intestinal	  cells	   into	  M	  cells.	  The	  biological	  assays	  for	  RANK-­‐02	  yielded	  species-­‐specific	  
results:	  an	  antagonist	  activity	  was	  observed	  for	  mRANK	  and	  an	  agonist	  effect	  was	  seen	  for	  the	  human	  
orthologue.	   However,	   its	   antagonist	   effect	   was	   weaker	   than	   that	   seen	   with	   anti-­‐RANKL	   IK22-­‐5	  
antibody,	  and	  the	  agonist	  activity	  may	  only	  have	  been	  detectable	  because	  of	  the	  high	  sensitivity	  of	  
the	   cellular	   assays.	   In	   vivo,	   RANK-­‐02	   proved	   unable	   to	   inhibit	   recombinant	   RANKL-­‐stimulated	  
osteoclast	   activity.	   The	   competitive	   ELISA	   assay	   showed	   that	   RANK-­‐02	   competed	   at	   low	  
12	  
	  
concentrations	  with	  mouse	  and	  human	  RANKL	  for	  binding	  to	  hRANK.	  Thus,	  the	  capacity	  of	  RANK-­‐02	  
to	   interfere	   with	   receptor-­‐ligand	   interaction	   can	   explain	   its	   in	   vitro	   antagonist	   activity,	   while	   its	  
agonist	   activity	   is	   likely	   triggered	   by	   its	   direct	   binding	   to	   RANK.	   EDAR	   is	   like	   RANK	   a	   TNF	   family	  
member,	  and	  in	  a	  previous	  study	  characterizing	  a	  panel	  of	  anti-­‐EDAR	  antibodies,	  it	  was	  found,	  using	  
EDAR:Fas	   reporter	  cells,	   that	  several	  antibodies	  were	  agonist	   in	   this	  system	  while	  others	  were	  not.	  
What	  correlated	  with	  agonist	  activity	  in	  this	  experimental	  system	  was	  not	  the	  affinities	  of	  antibodies,	  
but	  their	  ability	  to	  detach	  slowly	  once	  bound	  (small	  koff)	  [42].	  Interestingly,	  RANK-­‐02	  and	  R12-­‐31	  have	  
the	   same	   affinity	   for	   mRANK	   but	   R12-­‐31	   has	   a	   lower	   koff	   rate.	   Differences	   in	   agonist	   activities	  
between	  RANK-­‐02	  and	  R12-­‐31	  might	  also	  reflect	  binding	  epitopes	  that	  may	  be	  more	  or	  less	  favorable	  
for	  generating	  an	  active	  conformation	  of	  the	  receptor.	   Indeed,	  we	  found	  that	  the	  mAbs	  recognized	  
distinct	   epitopes	   on	   RANK.	   RANK-­‐02	   proved	   to	   be	   an	   excellent	   reagent	   for	   the	   detection	   of	  
endogenous	  RANK	  on	  primary	  human	  skin	  Langerhans	  cells	  by	  FACS.	  A	   staining	  protocol	  with	  both	  
antibodies	  would	  provide	  a	  strong	  guarantee	  of	  specificity	  because	  they	  recognize	  distinct	  epitopes,	  
implying	  that	  if	  these	  antibodies	  cross-­‐react	  with	  other	  antigens,	  these	  are	  unlikely	  to	  be	  shared.	  We	  
confirm	  using	  primary	  human	  skin	  cells	   that	  Langerhans	  cells	  express	  high	   levels	  of	  RANK,	  whereas	  
CD14-­‐	   dendritic	   cells	   express	  RANK	  weakly	   and	  CD14+	  dendritic	   cells	   none.	   It	   has	  been	   shown	   that	  
RANK	  expression	  by	  dendritic	  cells,	  inclusive	  Langerhans	  cells,	  prolongs	  cell	  survival	  [4,18],	  which	  may	  
also	   endow	   Langerhans	   cells	   exiting	   the	   skin	   to	   prolong	   interaction	   with	   T	   cells.	   Indeed,	   human	  
Langerhans	   cells	   have	   been	   shown	   to	   be	  more	   potent	   T	   cell	   activators	   than	   dermal	   dendritic	   cells	  
[45].	   Interestingly,	   RANK	   has	   also	   been	   implicated	   in	   the	   formation	   of	   regulatory	   T	   cells	   [12],	  
suggesting	   an	   implication	   of	   RANK	   in	   the	   regulation	   of	   immunity	   by	   Langerhans	   cells	   [46-­‐48].	   Hair	  
follicles	  in	  their	  growth	  phase	  are	  a	  natural	  source	  of	  RANKL	  [31],	  and	  this	  phase	  of	  the	  hair	  cycle	  is	  
characterized	   by	   a	   reduced	   delayed-­‐type	   hypersensitivity	   response	   [49],	   a	   cutaneous	   reaction	  
implicating	   Langerhans	   cells.	   Intestinal	   M	   cells	   are	   specialized	   epithelial	   cells	   implicated	   in	   the	  
transport	   of	   antigen	   from	   the	   lumen	   to	   underlying	   cells.	   Peyer’s	   patches	   and	   isolated	   lymphoid	  
follicles	  comprise	  numerous	  M	  cells	  to	  help	  generate	  immune	  responses	  against	  intestinal	  microflora.	  
M	  cells	  are	  absent	   in	  RANKL	  or	  Spi-­‐B	  knock-­‐out	  mice	  entailing	  the	  failure	  of	  the	   immune	  system	  to	  
respond	  to	  intestinal	  pathogens.	  Administration	  of	  recombinant	  RANKL	  has	  been	  shown	  to	  restore	  M	  
cells	   in	  RANKL-­‐/-­‐	  mice	  and	   leads	   to	  an	   increase	   in	  M	  cells	  on	   small	   intestinal	   villi	   [25,26].	  Here	  we	  
show	   that	  RANK	  agonist	  R12-­‐31	   likewise	   leads	   to	  ectopic	  M	  cell	   differentiation	  of	   villous	  epithelial	  




In	  conclusion,	  we	  have	  performed	  a	  detailed	  characterization	  of	  two	  anti-­‐RANK	  mAbs	  with	  respect	  to	  
affinity,	  specificity,	  activity	  and	  applications.	  These	  findings	  should	  help	  advance	  our	  understanding	  
of	  RANK-­‐RANKL-­‐OPG	  biology	  and	  pave	  the	  way	  for	  their	  use	  in	  vitro	  and	  in	  vivo.	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Figure	  legends	  
Figure	   1.	   RANK-­‐directed	   antibodies	   RANK-­‐02	   and	   R12-­‐31	   bind	   to	   the	   mouse	   RANK	   extracellular	  
domain.	   (A)	   Recognition	   of	   mouse	   RANK-­‐Fc	   fusion	   protein	   by	   ELISA.	   Data	   is	   expressed	   as	   color	  
production	   (absorbance	   at	   450	   nm)	   by	   enzyme-­‐coupled	   secondary	   antibody	   recognizing	   increasing	  
concentrations	  of	  RANK-­‐02	  and	  R12-­‐31	  bound	  to	  fixed	  concentration	  of	  surface-­‐attached	  mRANK-­‐Fc.	  
(B)	   Detection	   by	   flow	   cytometry	   of	  mouse	   RANK	   stably	   expressed	   either	   by	   Jurkat	   JOM2	   cells	   (as	  
fusion	  protein	  between	  the	  RANK	  extracellular	  domain	  and	  the	  intracellular	  domain	  of	  human	  Fas)	  or	  
by	   HEK	   293	   cells	   (as	   full-­‐length	   RANK).	   Primary	   antibodies	   were	   either	   RANK-­‐02	   or	   R12-­‐31	   and	  
secondary	  antibodies	  were	  donkey	  anti-­‐human	  immunoglobulin	  or	  donkey	  anti-­‐rat	  immunoglobulin,	  
respectively,	   conjugated	   to	  phycoerythrin.	   Controls	  were	  untransfected	   cells	   and	  primary	   antibody	  
isotypes.	  Data	  is	  representative	  of	  5	  independent	  experiments.	  	  
Figure	  2.	  The	  anti-­‐RANK	  antibodies	  have	  different	  biological	  activities	  on	  mouse	  RANK.	   (A)	  Dose-­‐
response	   curve	   of	   R12-­‐31	   antibody	   on	   Jurkat	   JOM2	   cells	   expressing	   or	   not	  mRANK:Fas.	   The	   graph	  
displays	  %	  cell	  viability	  relative	  to	  Jurkat	  JOM2	  cells	  grown	  in	  the	  absence	  of	  antibody	  (non-­‐treated,	  
NT)	  as	  a	  function	  of	   increasing	  concentrations	  of	  R12-­‐31.	  Data	  points	  are	  the	  mean	  (±	  SD,	  n=3	  with	  
duplicate	  wells).	  Curve	  fitting	  was	  performed	  using	  the	  PRISM	  software.	  (B)	  As	  for	  panel	  A,	  but	  using	  
the	  antibody	  RANK-­‐02.	  (C)	  NF-­‐κB	  activation	  by	  R12-­‐31	  of	  HEK	  293	  cells	  stably	  expressing	  full-­‐length	  
murine	   RANK	   and	   transfected	   with	   an	   NF-­‐κB	   responsive	   luciferase	   reporter	   gene	   and	   a	   β-­‐
galactosidase	   expressing	   transfection	   control	   plasmid.	   Data	   are	   the	   mean	   %	   relative	   to	   RANKL-­‐
activated	  cells	  (±	  SD,	  n=3	  with	  duplicate	  wells).	  Data	  are	  for	  0.1	  µg/ml	  RANKL	  and	  25	  µg/ml	  R12-­‐31	  
antibody.	  NT=	  non-­‐treated	  cells.	  (D)	  As	  for	  panel	  B,	  but	  using	  RANK-­‐02	  antibody	  (50	  µg/ml).	  (E)	  The	  
antagonist	   activity	   of	   RANK-­‐02	   was	   tested	   by	   its	   capacity	   to	   block	   mRANK:Fas-­‐mediated	   cell	  
apoptosis	  triggered	  by	  recombinant	  GST-­‐mRANKL.	  The	  graph	  presents	  JOM2	  mRANK:Fas	  cell	  viability	  
in	  the	  absence	  or	  presence	  of	  recombinant	  RANKL,	   the	  RANKL-­‐blocking	  antibody	   IK22-­‐5	  and	  RANK-­‐
02,	  relative	  to	  non-­‐treated	  cells	  (NT).	  RANKL	  was	  used	  at	  1	  ng/ml,	  IK22-­‐5	  at	  10	  µg/ml	  and	  RANK-­‐02	  at	  
17	  
	  
50	  µg/ml.	  (F)	  The	  antagonist	  effect	  of	  RANK-­‐02	  was	  tested	  by	  its	  capacity	  to	  block	  NF-­‐κB	  activation	  
elicited	  by	  recombinant	  RANKL.	  Data	  are	  expressed	  as	  the	  mean	  %	  (±	  SD,	  n=3	  with	  duplicate	  wells)	  
relative	   to	  RANKL-­‐induced	  NF-­‐κB	  activation.	  RANKL	  was	  used	  at	  0.1	  µg/ml,	   IK22-­‐5	  at	  10	  µg/ml	  and	  
RANK-­‐02	   at	   50	   µg/ml.	   For	   data	   panels	   C-­‐F,	   statistical	   significance	   was	   calculated	   by	   one	   way	  
Anova/Bonferroni	  using	  the	  PRISM	  software.	  	  
Figure	   3.	   RANK-­‐directed	   antibodies	   RANK-­‐02	   and	   R12-­‐31	   bind	   to	   the	   human	   RANK	   extracellular	  
domain.	   (A)	   Recognition	   of	   human	   RANK-­‐Fc	   fusion	   protein	   by	   ELISA.	   Data	   is	   expressed	   as	   color	  
production	   (absorbance	   at	   450	   nm)	   by	   enzyme-­‐coupled	   secondary	   antibody	   recognizing	   increasing	  
concentrations	  of	  RANK-­‐02	  and	  R12-­‐31	  bound	   to	   fixed	  concentration	  of	   surface-­‐attached	  RANK-­‐Fc.	  
(B)	  Detection	  by	  flow	  cytometry	  of	  human	  RANK	  stably	  expressed	  either	  by	  Jurkat	  JOM2	  cells	   (as	  a	  
fusion	  protein	  between	  the	  RANK	  extracellular	  domain	  and	  the	  intracellular	  domain	  of	  human	  Fas)	  or	  
by	   HEK	   293	   cells	   (as	   full-­‐length	   RANK).	   Detection	   was	   performed	   as	   described	   in	   Fig.	   1B.	   Data	   is	  
representative	  of	  5	  independent	  experiments.	  
Figure	   4.	   Both	   antibodies	   are	   agonists	   on	   human	   RANK.	   (A)	   Dose-­‐response	   curve	   of	   the	   R12-­‐31	  
antibody	  on	  Jurkat	  JOM2	  cells	  expressing	  or	  not	  hRANK:Fas.	  The	  graph	  displays	  cell	  viability	  relative	  
to	  the	  percentage	  of	  Jurkat	  JOM2	  cells	  grown	  in	  the	  absence	  of	  antibody	  as	  a	  function	  of	  increasing	  
concentrations	  of	   anti-­‐RANK	  antibody	  R12-­‐31.	  Data	  points	   are	   the	  mean	   (±	   SD,	  n=3	  with	  duplicate	  
wells).	  Curve	  fitting	  was	  performed	  using	  the	  PRISM	  software.	  NT=	  non-­‐treated	  cells.	  (B)	  As	  for	  panel	  
A,	  but	  using	  the	  RANK-­‐02	  antibody.	   (C)	  The	  JOM2	  hRANK:Fas	  cell	  viability	  assay	  shows	  that	   isotype	  
controls	   for	  R12-­‐31	   (rat	   IgG2a,	  1	  µg/ml)	  and	   for	  RANK-­‐02	   (human	   IgG1,	  50	  µg/ml)	  have	  no	  human	  
RANK-­‐stimulating	   effect.	   (D)	   NF-­‐κB	   activation	   by	   R12-­‐31	   and	   RANK-­‐02	   antibodies	   in	   HEK	   293	   cells	  
stably	   expressing	   full-­‐length	   human	   RANK	   and	   transfected	   with	   an	   NF-­‐κB-­‐responsive	   luciferase	  
reporter	  gene.	  Data	  are	  the	  mean	  %	  relative	  to	  RANKL-­‐activated	  cells	  (±	  SD,	  n=3	  with	  duplicate	  wells).	  
Data	  is	  shown	  for	  0.1	  µg/ml	  RANKL,	  25	  µg/ml	  R12-­‐31	  and	  50	  µg/ml	  RANK-­‐02.	  NT=	  non-­‐treated	  cells.	  
Statistical	  significance	  was	  calculated	  by	  one	  way	  Anova/Bonferroni	  using	  the	  PRISM	  software.	  	  
Figure	  5.	  Analysis	  of	  shared	  or	  distinct	  epitopes.	  (A)	  RANKL	  blocking	  by	  the	  mAbs.	  ELISA	  plates	  were	  
coated	  with	   human	  RANK-­‐Fc,	   incubated	   first	  with	   the	  mAbs	   and	   then	  with	   human	   (left)	   or	  mouse	  
(right)	  RANKL.	  The	  amount	  of	  bound	  RANKL	  was	  measured.	  The	  data	  show	  that	  the	  binding	  sites	  of	  
RANK-­‐02	  and	  RANKL	  overlap,	  but	  that	  they	  are	  distinct	  for	  R12-­‐31	  and	  RANKL.	  (B)	  Competitive	  FACS	  
to	   determine	   RANK-­‐02	   /	   R12-­‐31	   distinct	   or	   shared	   epitopes.	   Jurkat	   JOM2	   mRANK:Fas	   and	   Jurkat	  
JOM2	  hRANK:Fas	  were	  incubated	  on	  ice	  for	  15	  min	  with	  increasing	  amounts	  of	  unlabeled	  competitor	  
antibody,	  followed	  without	  washing	  by	  a	  fixed	  concentration	  of	  biotinylated	  test	  mAb	  for	  20	  min	  on	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ice.	  Cells	  were	  then	  washed	  and	  the	  binding	  of	  test	  mAb	  revealed	  with	  PE-­‐conjugated	  streptavidin.	  
Graphs	  show	  that	  RANK-­‐02	  and	  R12-­‐31	  do	  not	  cross-­‐compete	  for	  binding	  to	  RANK-­‐expressing	  cells.	  	  
Figure	   6.	   The	   anti-­‐RANK	   mAbs	   recognize	   RANK	   on	   primary	   human	   Langerhans	   cells.	   (A)	   Flow	  
cytometry	  gating	  strategy	  to	  obtain	  three	  cell	  populations:	  Langerin+	  cells	   (population	   I),	  and	  CD14-­‐	  
and	  CD14+	  dermal	  dendritic	  cells	   (populations	   II	  and	  III,	   respectively).	  Dead	  cells	  are	  excluded	  using	  
the	  FVD	  stain.	  Human	  RANK	  expression	  by	  Langerhans	  cells	   (B),	  CD14-­‐	  dendritic	  cells	   (C)	  and	  CD14+	  
dendritic	  cells	  using	  both	  anti-­‐RANK	  mAbs	  and	  their	  isotype	  controls	  (in	  grey).	  (D).	  The	  percentage	  of	  
positive	  cells	  is	  indicated.	  (E)	  Mean	  percentage	  of	  RANK-­‐positive	  cells±	  SD	  measured	  with	  RANK-­‐02	  or	  
R12-­‐31	   staining	   in	   three	   different	   populations	   of	   dendritic	   cells	   isolated	   from	   three	   donors	   (n=3	  
donors).	   (F)	  mean	   of	   ΔMFI±	   SD	  measured	  with	   RANK-­‐02	   or	   R12-­‐31	   staining	   in	   the	   three	   different	  
populations	   of	   dendritic	   cells	   isolated	   from	   three	   donors	   (n=3).	   ΔMFI=	  MFI	   RANK	   antibody	   –	  MFI	  
isotype	  control.	  Statistical	  significance	  was	  calculated	  by	  two	  way	  Anova/Bonferroni	  using	  the	  PRISM	  
software.	  
Figure	  7.	  Assessment	  of	  biological	  activities	   in	  vivo.	  (A)	  RANK-­‐02	  antagonist	  activity	  was	  measured	  
as	   inhibition	  of	  osteoclast-­‐dependent	   release	  of	  TRACP	  5b	   into	  serum.	  The	  data	   is	   the	  mean	   (SEM,	  
n=4)	  of	  TRACP	  5b	   in	  mice	  mock	   treated	   (PBS),	  or	   injected	  with	  25	  µg	  GST-­‐mRANKL	  alone	  or	   in	   the	  
presence	   of	   increasing	   amounts	   of	   RANK-­‐02.	   (B,	   C)	   R12-­‐31	   agonist	   activity	  was	   determined	   as	   the	  
capacity	  to	  induce	  M	  cells	  in	  the	  proximal	  ileum	  of	  C57BL/6	  mice.	  (B)	  Whole	  mount	  staining	  for	  UEA-­‐
I+	  M	  cells	   in	  the	  proximal	   ileum,	  untreated	  or	  treated	  with	  GST-­‐mRANKL	  or	  R12-­‐31	  mAb	  for	  5	  days.	  
Nuclear	  counterstain	  was	  with	  DAPI.	  In	  untreated	  mice	  no	  villous	  M	  cells	  are	  found,	  whilst	  anti-­‐RANK	  
R12-­‐31	  mAb	   and	   recombinant-­‐mRANKL	   induce	   a	   large	   number	   of	   polygonal	   UEA-­‐I+	   villous	  M	   cells.	  
Scale	   bar	   is	   100	   µm.	   (C)	   The	   graph	   presents	   the	   cell	   counts	   of	   UEA-­‐I+	   M	   cells	   per	   villus	   of	   5	  
representable	  villous	  tips	  on	  the	  whole	  mount	   images	   in	  the	  three	  different	  conditions.	  Data	   is	   the	  
mean	  ±SD	  of	  five	  representative	  villous	  tips	  for	  each	  group.	  Statistical	  significance	  was	  calculated	  by	  
two	  way	  Anova/Bonferroni	  using	  the	  PRISM	  software.	  
	  
Supplemental	  Figure	  1.	  MFI	  of	  the	  flow	  cytometry	  RANK	  staining	  with	  the	  two	  mAbs	  (RANK-­‐02	  and	  
R12-­‐31)	  for	  the	  six	  different	  cell	  lines	  used.	  The	  data	  was	  derived	  from	  Figure	  1	  and	  3	  and	  the	  ΔMFI=	  
MFI	  RANK	  antibody	  –	  MFI	   isotype	  control	  was	  calculated.	  (A)	  ΔMFI	  for	  the	  Jurkat	  JOM2	  mRANK:Fas	  
cell	   line	   and	   its	   parental	   cell	   line	   Jurkat	   JOM2.	   (B)	   ΔMFI	   for	   the	   HEK	   293	  mRANK	   cell	   line	   and	   its	  
parental	  cell	  line.	  (C)	  Same	  as	  (A)	  but	  for	  Jurkat	  JOM2	  hRANK:Fas	  cell	  line.	  (D)	  same	  as	  (B)	  but	  for	  HEK	  
293	  hRANK	  cell	  line,	  n=3.	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Supplemental	   Figure	  2.	   (A)	  Dose	   response	   curve	   for	   recombinant	  mRANKL	   fused	   to	  GST	  on	   Jurkat	  
JOM2	  cells	  expressing	  or	  not	  mouse	  or	  human	  RANK:Fas.	  The	  graph	  displays	  the	  percentage	  of	  cell	  
viability	   relative	   to	   Jurkat	   JOM2	   cells	   grown	   in	   the	   absence	   of	   mRANKL	   (non-­‐treated,	   NT)	   as	   a	  
function	  of	  increasing	  concentrations	  of	  mRANKL.	  Data	  points	  are	  the	  mean	  (±	  SD,	  n=3	  with	  duplicate	  
wells).	  Curve	  fitting	  was	  performed	  using	  the	  PRISM	  software.	   (B)	  Cell	  viability	  of	  Jurkat	  JOM2	  cells	  
expressing	  or	  not	  mouse	  or	  human	  RANK:Fas	  fusion	  protein	  treated	  with	  0.1	  µg/ml	  GST	  only	  or	  0.1	  
µg/ml	  GST-­‐mRANKL.	  Data	  is	  the	  mean	  (±	  SD,	  n=3	  with	  duplicate	  wells)	  relative	  to	  JOM2	  cells	  exposed	  
to	  GST.	   (C)	   Same	  as	  panel	  A	  but	  with	  Fc-­‐mRANKL	  and	  Fc-­‐hRANKL.	  The	  hBAFFR:Fas	  cell	   line	  and	  Fc-­‐
hBAFF	  were	  used	  as	  a	  negative	  controls.	  (D)	  EC50	  values	  for	  results	  of	  panel	  C.	  	  
Supplementary	   Figure	   3.	   Competitive	   FACS	   to	   determine	   RANK-­‐02	   /	   R12-­‐31	   distinct	   or	   shared	  
epitopes.	   Cells	   in	   50	  µl	   FACS	  buffer	  were	   coated	   for	   15	  min	  on	   ice	  with	   100,	   200	  or	   500	  µg/ml	  of	  
RANK-­‐02	   (human	   anti-­‐RANK),	   or	   R12-­‐31	   (rat	   IgG2a	   anti-­‐RANK),	   or	  NIP288	   (ctrl	   for	   RANK-­‐02)	   or	   rat	  
IgG2a	  (ctrl	  for	  R12-­‐31)	  in	  6-­‐fold	  dilutions	  (10	  µl	  passed	  in	  50	  µl).	  Without	  washing,	  biotinylated	  RANK-­‐
02	  at	  10	  or	  50	  µg/ml	   (50	  or	  250	  ng/staining)	  or	  biotinylated	  R12-­‐31	  at	  20	  or	  50	  µg/ml	   (100	  or	  250	  
ng/staining)	  was	  added.	  After	  20	  min	  on	   ice,	   the	  cells	  were	  washed	  and	  biotinylated	  mAb	  revealed	  
with	  PE-­‐conjugated	  streptavidin.	  The	  histograms	  for	  each	  condition	  are	  shown.	  The	  dashed	  green	  line	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Binding of biotinylated anti-RANK antibodies [log scale, 102 to 106]
Supplementary Figure 3 
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